KRAS and carcinoma: According to the classical tumor progression model of sporadic CRC proposed by Fearon and Vogelstein, APC mutation is involved in adenoma formation, followed by KRAS oncogenic mutation that promotes the transition from intermediate adenomas to carcinomas, with TP53 inactivation as a late event [21].